Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-044281
Filing Date
2025-05-15
Accepted
2025-05-15 16:31:35
Documents
67
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0240596-10q_pasithea.htm   iXBRL 10-Q 551085
2 CERTIFICATION ea024059601ex31-1_pasi.htm EX-31.1 10213
3 CERTIFICATION ea024059601ex31-2_pasi.htm EX-31.2 10510
4 CERTIFICATION ea024059601ex32-1_pasi.htm EX-32.1 4319
5 CERTIFICATION ea024059601ex32-2_pasi.htm EX-32.2 4547
  Complete submission text file 0001213900-25-044281.txt   4753177

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ktta-20250331.xsd EX-101.SCH 44416
7 XBRL CALCULATION FILE ktta-20250331_cal.xml EX-101.CAL 31131
8 XBRL DEFINITION FILE ktta-20250331_def.xml EX-101.DEF 240149
9 XBRL LABEL FILE ktta-20250331_lab.xml EX-101.LAB 428655
10 XBRL PRESENTATION FILE ktta-20250331_pre.xml EX-101.PRE 246066
69 EXTRACTED XBRL INSTANCE DOCUMENT ea0240596-10q_pasithea_htm.xml XML 476965
Mailing Address 1111 LINCOLN ROAD, SUITE 500 MIAMI BEACH FL 33139
Business Address 1111 LINCOLN ROAD, SUITE 500 MIAMI BEACH FL 33139 (702) 514-4174
Pasithea Therapeutics Corp. (Filer) CIK: 0001841330 (see all company filings)

EIN.: 851591963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40804 | Film No.: 25954196
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)